Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 23;11(5):e4742.
doi: 10.7759/cureus.4742.

Spine Stereotactic Radiosurgery for Metastatic Pheochromocytoma

Affiliations

Spine Stereotactic Radiosurgery for Metastatic Pheochromocytoma

Shane Mesko et al. Cureus. .

Abstract

Purpose: Despite aggressive primary treatment, up to 13.5% of patients diagnosed with pheochromocytoma may develop metastases, most often affecting the axial skeleton. Given that systemic therapy options are often inadequate, local therapy remains the cornerstone of palliation for these patients. Historically poor responses to standard fractionated radiotherapy have led to the consideration of stereotactic radiosurgery as an option to overcome potential radioresistance and provide durable local control of these tumors. Here we report our institutional experience in treating spine metastases from pheochromocytoma with spine stereotactic radiosurgery (SSRS).

Methods and materials: Our clinical databases were retrospectively reviewed for patients with metastatic pheochromocytoma treated with SSRS from 2000-2017. Seven patients with 16 treated metastatic spinal lesions were identified. Local control was evaluated using magnetic resonance imaging (MRI). Pain and symptom data were assessed to evaluate toxicity using Common Terminology Criteria for Adverse Events (CTCAE) v4.03. The Kaplan-Meier method was used to assess local control and overall survival (OS).

Results: Median follow-up for treated lesions was 11 months (range 2.2 - 70.8). Most lesions were treated to a dose of 27 Gy in three fractions (62.5%). Other fractionation schemes included 24 Gy in one fraction (25%), 16 Gy in one fraction (6.3%), and 18 Gy in three fractions (6.3%). Treatment sites included the cervical spine (18.8%), thoracic spine (37.5%), lumbar spine (31.3%), and sacrum (12.5%). The crude local control rate was 93.7%, with one thoracic spine lesion progressing 20.7 months after treatment with 24 Gy in one fraction. Kaplan-Meier OS rates at 1 and 2 years after SSRS were 71.4% and 42.9%, respectively. Most common toxicities included acute grade 1-2 pain and fatigue. There was one case of vertebral fracture in a cervical spine lesion treated to 27 Gy in three fractions, which was managed non-surgically.

Conclusion: Very few studies have explored the use of SSRS in metastatic pheochromocytoma. Our data suggest this modern radiation modality is effective, safe, and provides durable local control to palliate symptoms and potentially limit further metastatic seeding. Larger patient numbers and longer follow-up will further define the role of SSRS as a treatment option in these patients.

Keywords: metastatic pheochromocytoma; pheochromocytoma; spine stereotactic radiosurgery; ssrs; stereotactic radiation.

PubMed Disclaimer

Conflict of interest statement

Dr. Shane Mesko has a consulting agreement with Oscar Healthcare, outside the submitted work. Dr. Jing Li has received research funding from Medtronic to support a different clinical trial on SSRS, outside the submitted work Dr. Paul Brown has received personal fees from UpToDate (contributor) and Novella Clinical (DMSB Member), outside the submitted work.

References

    1. Pheochromocytoma: current approaches and future directions. Adler JT, Meyer-Rochow GY, Chen H, Benn DE, Robinson BG, Sippel RS, Sidhu SB. Oncologist. 2008;13:779–793. - PubMed
    1. Changing paradigms in the treatment of malignant pheochromocytoma. Grogan RH, Mitmaker EJ, Duh QY. Cancer Control. 2011;18:104–112. - PubMed
    1. The vagaries of pheochromocytomas. Manger WM. Am J Hypertens. 2005;18:1266–1270. - PubMed
    1. Clinical experience over 48 years with pheochromocytoma. Goldstein RE, O'neill JA, Holcomb GW, et al. Ann Surg. 1999;229:755–764. - PMC - PubMed
    1. Clinical review: current treatment of malignant pheochromocytoma. Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H. J Clin Endocrinol Metab. 2007;92:1217–1225. - PubMed

LinkOut - more resources